Thor Medical (TRMED.OL) Stock Analysis & AI Equity Report
Thor Medical (TRMED.OL) overview
Thor Medical (TRMED.OL) stock analysis and AI equity research. For the latest completed financial year, 2024, Thor Medical reported revenue of NOK 0m and operating profit of NOK -52.7m; the year-end share price was 2.63 NOK and market capitalisation was NOK 620m. Thor Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Thor Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-12-12. Data will be refreshed during report generation.
About Thor Medical
Thor Medical ASA develops and supplies alpha-particle emitters for radiopharmaceutical companies working on targeted cancer therapies. The company uses a proprietary production process based on naturally occurring thorium, without nuclear reactors or irradiation, to produce high-purity isotopes. It operates pilot-scale production in Norway and is developing larger-scale capacity for commercial deliveries.
Generate the Thor Medical report
Thor Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Thor Medical and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.